| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Katharine S Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul G Richardso. Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. American journal of hematology. 2024-04-16. PMID:38622840. |
here, we present patient-reported outcomes (pros) collected using the european organisation for research and treatment of cancer (eortc) quality of life questionnaire core 30-item (qlq-c30), eortc quality of life questionnaire multiple myeloma module 20-item (qlq-my20), and euroqol 5-dimension 5-level (eq-5d-5l) tools on day 1 of cycles 1, 2, and 3; on day 21 of cycle 4 (end of induction therapy); on day 1 of cycle 5; on day 21 of cycle 6 (end of posttransplant consolidation therapy); and at months 6, 12, 18, and 24 of maintenance therapy. |
2024-04-16 |
2024-04-18 |
Not clear |
| Heinz Ludwig, Pieter Sonneveld, Faith Davies, Joan Bladé, Mario Boccadoro, Michele Cavo, Gareth Morgan, Javier de la Rubia, Michel Delforge, Meletios Dimopoulos, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Philippe Moreau, Hareth Nahi, Torben Plesner, Jesús San-Miguel, Roman Hajek, Pia Sondergeld, Antonio Palumb. European perspective on multiple myeloma treatment strategies in 2014. The oncologist. vol 19. issue 8. 2015-04-10. PMID:25063227. |
consolidation and maintenance therapy are attractive strategies not yet approved by the european medicines agency, and a decision regarding post-asct therapy should only be made after detailed discussion of the pros and cons with the individual patient. |
2015-04-10 |
2023-08-13 |
Not clear |
| Michele Cavo, Annamaria Brioli, P Tacchetti, B A Zannetti, K Mancuso, E Zamagn. Role of consolidation therapy in transplant eligible multiple myeloma patients. Seminars in oncology. vol 40. issue 5. 2013-12-12. PMID:24135406. |
this review will focus on recent trials of novel agents as post-asct consolidation therapy, offering an overview of pros and cons of this new treatment strategy in the asct sequence for mm patients. |
2013-12-12 |
2023-08-12 |
Not clear |
| Thomas Elter, Barbara F Eichhorst, Clemens-Martin Wendtne. Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons. Current hematologic malignancy reports. vol 4. issue 1. 2010-07-28. PMID:20425437. |
use of alemtuzumab and rituximab consolidation in cll: pros and cons. |
2010-07-28 |
2023-08-12 |
Not clear |